Patents by Inventor Louie Naumovski

Louie Naumovski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
    Publication number: 20230321271
    Abstract: The present disclosure provides antibody drug conjugates that bind human cMET, their methods of making, and their uses to treat patients having cancer.
    Type: Application
    Filed: February 22, 2023
    Publication date: October 12, 2023
    Applicants: AbbVie Biotherapeutics Inc., AbbVie Inc.
    Inventors: Christian B. Allan, Louie Naumovski, Edward B. Reilly
  • ANTI-DLL4/VEGF DUAL VARIABLE DOMAIN IMMMUNOGLOBULIN AND USES THEREOF
    Publication number: 20220403052
    Abstract: Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases diseases characterized by aberrant DLL4 and/or VEGF expression or activity.
    Type: Application
    Filed: January 28, 2022
    Publication date: December 22, 2022
    Inventors: Jijie Gu, Dominic J. Ambrosi, Susan E. Lappe, Yingchun Li, Jonathan A. Hickson, Deanna L. Haasch, Supriya Gupta, Ravi Chari, Camellia Zamiri, Louie Naumovski, Xianhua Cao
  • ABT-165 IN COMBINATION WITH FOLINIC ACID, 5-FLUOROURACIL, AND IRINOTECAN FOR THE TREATMENT OF CANCERS
    Publication number: 20220211846
    Abstract: This invention pertains to a method for the treatment of cancer in a subject comprising administering to the subject an effective amount of ABT-165 in combination with folinic acid, 5-fluorouracil and irinotecan (FOLFIRI).
    Type: Application
    Filed: August 17, 2021
    Publication date: July 7, 2022
    Inventor: Louie Naumovski
  • ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
    Publication number: 20200215200
    Abstract: The present disclosure provides antibody drug conjugates that bind human cMET, their methods of making, and their uses to treat patients having cancer.
    Type: Application
    Filed: January 17, 2020
    Publication date: July 9, 2020
    Inventors: Christian B. ALLAN, Louie NAUMOVSKI, Edward B. REILLY
  • Anti-cMet antibody drug conjugates and methods for their use
    Patent number: 10603389
    Abstract: The present disclosure provides antibody drug conjugates that bind human cMET, their methods of making, and their uses to treat patients having cancer.
    Type: Grant
    Filed: May 28, 2019
    Date of Patent: March 31, 2020
    Assignees: AbbVie Inc., AbbVie Biotherapeutics Inc.
    Inventors: Christian B. Allan, Louie Naumovski, Edward B. Reilly
  • ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
    Publication number: 20190314518
    Abstract: The present disclosure provides antibody drug conjugates that bind human cMET, their methods of making, and their uses to treat patients having cancer.
    Type: Application
    Filed: May 28, 2019
    Publication date: October 17, 2019
    Inventors: Christian B. ALLAN, Louie NAUMOVSKI, Edward B. REILLY
  • Anti-cMet antibody drug conjugates and methods for their use
    Patent number: 10383948
    Abstract: The present disclosure provides antibody drug conjugates that bind human cMET, their methods of making, and their uses to treat patients having cancer.
    Type: Grant
    Filed: March 2, 2018
    Date of Patent: August 20, 2019
    Assignees: AbbVie Inc., AbbVie Biotherapeutics Inc.
    Inventors: Christian B. Allan, Mark Anderson, Louie Naumovski, Edward B. Reilly, Jieyi Wang
  • ABT-165 IN COMBINATION WITH FOLINIC ACID, 5-FLUOROURACIL, AND IRINOTECAN FOR THE TREATMENT OF CANCERS
    Publication number: 20190167790
    Abstract: This invention pertains to a method for the treatment of cancer in a subject comprising administering to the subject an effective amount of ABT-165 in combination with folinic acid, 5-fluorouracil and irinotecan (FOLFIRI).
    Type: Application
    Filed: December 3, 2018
    Publication date: June 6, 2019
    Inventor: Louie Naumovski
  • Anti-CS1 antibodies and antibody drug conjugates
    Patent number: 10308713
    Abstract: The present disclosure provides antibodies and antibody drug conjugates that bind human CS1 and their uses to treat subjects diagnosed with a plasma cell neoplasm, for example, multiple myeloma.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: June 4, 2019
    Assignee: AbbVie Biotherapeutics Inc.
    Inventors: Kurt C. Gish, Han K. Kim, Louie Naumovski
  • ANTI-DLL4/VEGF DUAL VARIABLE DOMAIN IMMUNOGLOBULIN AND USES THEREOF
    Publication number: 20190031783
    Abstract: Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases diseases characterized by aberrant DLL4 and/or VEGF expression or activity.
    Type: Application
    Filed: March 7, 2018
    Publication date: January 31, 2019
    Inventors: Jijie Gu, Dominic J. Ambrosi, Susan E. Lappe, Yingchun Li, Jonathan A. Hickson, Deanna L. Haasch, Supriya Gupta, Ravi Chari, Camellia Zamiri, Louie Naumovski, Xianhua Cao
  • ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
    Publication number: 20180250418
    Abstract: The present disclosure provides antibody drug conjugates that bind human cMET, their methods of making, and their uses to treat patients having cancer.
    Type: Application
    Filed: March 2, 2018
    Publication date: September 6, 2018
    Inventors: Daniel E.H. AFAR, Christian B. ALLAN, Mark ANDERSON, Louie NAUMOVSKI, Edward B. REILLY, Jieyi WANG
  • ANTI-CS1 ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    Publication number: 20180222979
    Abstract: The present disclosure provides antibodies and antibody drug conjugates that bind human CS1 and their uses to treat subjects diagnosed with a plasma cell neoplasm, for example, multiple myeloma.
    Type: Application
    Filed: November 21, 2017
    Publication date: August 9, 2018
    Inventors: Kurt C. GISH, Han K. Kim, Louie Naumovski
  • Anti-CS1 antibodies and antibody drug conjugates
    Patent number: 10011657
    Abstract: The present disclosure provides antibodies and antibody drug conjugates that bind human CS1 and their uses to treat subjects diagnosed with a plasma cell neoplasm, for example, multiple myeloma.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: July 3, 2018
    Assignee: AbbVie Biotherapeutics Inc.
    Inventors: Kurt C. Gish, Han K. Kim, Louie Naumovski
  • Anti-DLL4/VEGF dual variable domain immunoglobulin and uses thereof
    Patent number: 9944720
    Abstract: Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases diseases characterized by aberrant DLL4 and/or VEGF expression or activity.
    Type: Grant
    Filed: September 4, 2015
    Date of Patent: April 17, 2018
    Assignee: AbbVie Inc.
    Inventors: Jijie Gu, Dominic J. Ambrosi, Susan E. Lappe, Yingchun Li, Jonathan A. Hickson, Deanna L. Haasch, Supriya Gupta, Ravi Chari, Camellia Zamiri, Louie Naumovski, Xianhua Cao
  • ANTI-cMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
    Publication number: 20170348429
    Abstract: The present disclosure provides antibody drug conjugates that bind human cMET, their methods of making, and their uses to treat patients having cancer.
    Type: Application
    Filed: May 17, 2017
    Publication date: December 7, 2017
    Inventors: EDWARD B. REILLY, LOUIE NAUMOVSKI, CHRISTIAN B. ALLAN, JIEYI WANG, MARK G. ANDERSON, DANIEL E. AFAR
  • ANTI-DLL4/VEGF DUAL VARIABLE DOMAIN IMMUNOGLOBULIN AND USES THEREOF
    Publication number: 20160122439
    Abstract: Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases diseases characterized by aberrant DLL4 and/or VEGF expression or activity.
    Type: Application
    Filed: September 4, 2015
    Publication date: May 5, 2016
    Inventors: Jijie Gu, Dominic J. Ambrosi, Susan E. Lappe, Yingchun Li, Jonathan A. Hickson, Deanna L. Haasch, Supriya Gupta, Ravi Chari, Camellia Zamiri, Louie Naumovski, Xianhua Cao
  • ANTI-CS1 ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    Publication number: 20160122430
    Abstract: The present disclosure provides antibodies and antibody drug conjugates that bind human CS1 and their uses to treat subjects diagnosed with a plasma cell neoplasm, for example, multiple myeloma.
    Type: Application
    Filed: October 30, 2015
    Publication date: May 5, 2016
    Inventors: Kurt C. Gish, Han K. Kim, Louie Naumovski
  • Anti-DLL4/VEGF dual variable domain immunoglobulin and uses thereof
    Patent number: 9163093
    Abstract: Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases characterized by aberrant DLL4 and/or VEGF expression or activity.
    Type: Grant
    Filed: October 31, 2013
    Date of Patent: October 20, 2015
    Assignee: AbbVie Inc.
    Inventors: Jijie Gu, Dominic J. Ambrosi, Susan E. Lappe, Yingchun Li, Jonathan A. Hickson, Deanna L. Haasch, Supriya Gupta, Ravi Chari, Camellia Zamiri, Louie Naumovski, Xianhua Cao
  • Anti-DLL4/VEGF dual variable domain immunoglobulin and uses thereof
    Patent number: 9045551
    Abstract: Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases characterized by aberrant DLL4 and/or VEGF expression or activity.
    Type: Grant
    Filed: June 11, 2014
    Date of Patent: June 2, 2015
    Assignee: AbbVie Inc.
    Inventors: Jijie Gu, Dominic J. Ambrosi, Susan E. Lappe, Yingchun Li, Jonathan A. Hickson, Deanna L. Haasch, Supriya Gupta, Ravi Chari, Camellia Zamiri, Louie Naumovski, Xianhua Cao
  • ANTI-DLL4/VEGF DUAL VARIABLE DOMAIN IMMUNOGLOBULIN AND USES THEREOF
    Publication number: 20140348835
    Abstract: Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases diseases characterized by aberrant DLL4 and/or VEGF expression or activity.
    Type: Application
    Filed: June 11, 2014
    Publication date: November 27, 2014
    Inventors: Jijie Gu, Dominic J. Ambrosi, Susan E. Lappe, Yingchun Li, Jonathan A. Hickson, Deanna L. Haasch, Supriya Gupta, Ravi Chari, Camellia Zamiri, Louie Naumovski, Xianhua Cao